MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis. Background:…
  • 2017 International Congress

    Long-term effect of botulinum toxin injection in the external oblique muscle to treat camptocormia in three patients with Parkinson’s disease.

    H. Todo (Sanda, Japan)

    Objective: To examine long-term effect of botulinum toxin injection (BTX) in the external oblique muscle (EO) for camptocormia associated with Parkinson’s disease (PD). Background: Camptocormia…
  • 2017 International Congress

    WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

    D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)

    Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…
  • 2017 International Congress

    Which factors predict patient satisfaction with botulinum toxin treatment for cervical dystonia?

    C. Colosimo, V. Misra, D. Charles, T.M. Chung, S. Om, P. Maisonobe (Terni, Italy)

    Objective: Investigate which factors influence patient satisfaction with botulinum neurotoxin type A (BoNT-A) treatment for cervical dystonia (CD) in routine practice. Background: We have previously…
  • 2017 International Congress

    Development of a New Kinematic Model for Head and Neck Movement Assessment in Cervical Dystonia

    A. Castagna, D. Anastasi, A. Crippa, L. Lanzotti, A. Montesano, A. Marzegan (Milano, Italy)

    Objective: The aim of this study is the development of a new kinematic model for cervical spine to assess abnormal head and neck postures and…
  • 2017 International Congress

    Prevelance,clinical pathology and Treatment of Dystonia in Pakistani Population

    S. Naureen, A. Arshad, N. Ahmad (RAWALPINDI, Pakistan)

    Objective:  Evaluate the gender,mean age,clinical spectrum and non–motor symptoms of the disease in Pakistan,a developing country of South East Asia. Background: Dystonia,a neurological syndrome,is characterized…
  • 2017 International Congress

    NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy

    B. Balint, G. Charlesworth, M. Stamelou, L. Carr, N. Wood, K. Bhatia (London, United Kingdom)

    Objective:  To elucidate the genetic cause of a distinct combined dystonia syndrome, inherited in an autosomal recessive fashion in a small UK kindred [Figure1A]. Background:…
  • 2017 International Congress

    Clinical and electrophysiological features of seven patients with moving toes syndrome: Is it a type of spinal segmental myoclonus?

    G. Kiziltan, H. Kurucu, C. Yalcinkaya, A. Gunduz, M. E. Kiziltan (Istanbul, Turkey)

    Objective: We aimed to present a case series of moving toes syndrome to show how clinical presentation and electrophysiological findings may change. Background: The moving…
  • 2017 International Congress

    Management of fragility fractures in Parkinson’s Disease (PD)

    G. Alg, A. Chatterjee (Reading, United Kingdom)

    Objective: To assess the management of osteoporotic fragility fractures in patients with PD attending a Movement disorders clinic. Background: Patients with PD have a high…
  • 2017 International Congress

    End of Life Care in Parkinson’s Disease

    S. Mole, S. Jackson (Exeter, United Kingdom)

    Objective: We aim to identify the current practice at the Royal Devon & Exeter NHS trust of managing Patients with PD at the end of…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley